GLP-1 & compounded medication availability in Georgia (2026)

Georgia is a baseline state in the truest sense: its rulebook holds compounding pharmacies to the national USP standards, requires out-of-state pharmacies to carry a Georgia permit, and adds nothing medication-specific on top for the ten lines we track. We checked the state’s own compounding chapter and licensure rules rather than assuming, and the citations are below. Here is what ships to Georgia addresses today, line by line, including the two lines that do not.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to Georgia: all ten lines

Availability of all ten OrderlyMeds product lines in Georgia, with typical delivery times and notes
Product lineAvailable in Georgia?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Filled on patient-specific prescriptions; partner pharmacies hold Georgia nonresident permits.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Identical flow to the semaglutide row at a flat national price.
NAD+ Yes 8–10 business days Ships from licensed partner pharmacies permitted for Georgia.
Sermorelin Yes 8–10 business days Longevity family; standard ordering flow.
Glutathione No N/A Not in the OrderlyMeds formulary today.
BPC-157 Yes 8–10 business days Compounded injectable. Federal record below.
TB-500 Yes 8–10 business days Compounded injectable; see its own section.
KPV No N/A Not carried in any state; our peptide lines are injectables only.
Epitalon Yes 8–10 business days Compounded injectable; federal standing below.
MOTS-c Yes 8–10 business days Compounded injectable; its federal record is its own, below.

Every line we track appears here, shipping or not. That is the point of the table. Georgia facts were last reviewed on November 16, 2026.

Research peptides in Georgia: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Georgia gets the same honest treatment as every state on this page: BPC-157, TB-500, Epitalon and MOTS-c are in the OrderlyMeds formulary as compounded injectables on patient-specific prescriptions, KPV is not carried at all, and none of that changes what each substance’s federal record says. Georgia’s rulebook holds the pharmacies doing this compounding to USP standards and says nothing peptide-specific; the federal facts below are therefore the operative ones, and they ship on this page whether a line is available to you or not.

BPC-157 in Georgia

Georgia orders for BPC-157 are filled as compounded injectables on patient-specific prescriptions. The two federal facts below are the ones that matter.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Georgia

TB-500 ships to Georgia addresses as a compounded injectable, dispensed on a patient-specific prescription. Its federal record follows.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Georgia

We do not carry KPV for Georgia or any state, because our peptide lines are compounded as injectables only and KPV is not one of them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Georgia

Epitalon is available to Georgia addresses as a compounded injectable under a patient-specific prescription. Its federal standing is set out below.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Georgia

MOTS-c ships to Georgia as a compounded injectable on a patient-specific prescription. Its federal record is distinct from the four lines above, so read it below as written.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Georgia’s pharmacy regulators say about compounded medications

Georgia’s approach is rulebook-first. The state publishes its pharmacy rules as numbered chapters, and the two that matter for this page are the compounding chapter and the licensure chapter covering out-of-state pharmacies. Neither singles out any of the ten lines on this page; board meetings in 2024 and 2025 heard industry presentations about compounded GLP-1s and peptide products, but no medication-specific rule or guidance has followed.

Georgia governs pharmaceutical compounding under Rules of the State Board of Pharmacy Chapter 480-11, which holds non-sterile compounded preparations to USP 795 and sterile compounded preparations to USP 797; no GLP-1-specific or peptide-specific prohibition appears in the chapter or has been published by the board. Source: Georgia Rules & Regulations, Chapter 480-11 (Pharmaceutical Compounding).

Out-of-state pharmacies shipping prescriptions to Georgia patients must hold a nonresident pharmacy permit under the board’s licensure rules, and a nonresident pharmacy that compounds must meet the same Chapter 480-11 standards, including a recent inspection report at application. Source: Georgia Rules & Regulations, Chapter 480-6 (Pharmacy Licenses).

Georgia permits prescribing on the basis of a telehealth encounter that meets the state’s standard of care. Source: Center for Connected Health Policy (CCHP) Policy Finder.

For a Georgia patient the practical picture is simple: the state’s requirements attach to the pharmacy and the prescriber, not to the medication list. An OrderlyMeds order runs through an online eligibility check, an evaluation by a Georgia-licensed provider, and fulfillment by a permitted partner pharmacy, at the same national price shown on our pricing page, at every dose.

Georgia availability FAQs

Is compounded semaglutide available in Georgia?

Yes. OrderlyMeds ships compounded semaglutide to Georgia addresses on patient-specific prescriptions, through partner pharmacies holding Georgia nonresident permits. New customers start at $74/month for the first two months.

Do I need an in-person doctor visit to get started in Georgia?

No. An evaluation by a Georgia-licensed provider over telehealth is how every OrderlyMeds order starts; the regulator section above carries the cited detail.

Can I get BPC-157 or other research peptides shipped to Georgia?

Four of the five: BPC-157, TB-500, Epitalon and MOTS-c ship to Georgia as compounded injectables on patient-specific prescriptions. KPV does not, because we compound these lines as injectables only. Each section above states that line’s own federal record, which applies regardless of where you buy.

How long does delivery to Georgia take?

Our published window is 8–10 business days from signup.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone